Magda Opsomer

851 total citations
29 papers, 517 citations indexed

About

Magda Opsomer is a scholar working on Infectious Diseases, Virology and Emergency Medicine. According to data from OpenAlex, Magda Opsomer has authored 29 papers receiving a total of 517 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Infectious Diseases, 19 papers in Virology and 5 papers in Emergency Medicine. Recurrent topics in Magda Opsomer's work include HIV/AIDS drug development and treatment (23 papers), HIV Research and Treatment (19 papers) and HIV/AIDS Research and Interventions (10 papers). Magda Opsomer is often cited by papers focused on HIV/AIDS drug development and treatment (23 papers), HIV Research and Treatment (19 papers) and HIV/AIDS Research and Interventions (10 papers). Magda Opsomer collaborates with scholars based in Belgium, United States and United Kingdom. Magda Opsomer's co-authors include Tom Van de Casteele, Erkki Lathouwers, Thomas N. Kakuda, Chloe Orkin, Homayoon Khanlou, E DeJesus, Albrecht Stoehr, Éric Lefebvre, K Supparatpinyo and Romana Petrovic and has published in prestigious journals such as The American Journal of Cardiology, AIDS and Theriogenology.

In The Last Decade

Magda Opsomer

29 papers receiving 510 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Magda Opsomer Belgium 12 422 293 123 78 51 29 517
Pavel Khaykin Germany 10 226 0.5× 195 0.7× 83 0.7× 249 3.2× 73 1.4× 30 530
Lorant Leopold United States 9 500 1.2× 347 1.2× 54 0.4× 258 3.3× 42 0.8× 14 663
Romina Quercia United Kingdom 10 408 1.0× 335 1.1× 114 0.9× 75 1.0× 27 0.5× 16 491
David Pizzuti United States 5 490 1.2× 386 1.3× 317 2.6× 109 1.4× 55 1.1× 5 687
S Staszewski Germany 8 393 0.9× 268 0.9× 221 1.8× 96 1.2× 28 0.5× 25 494
Frank Tomaka United States 12 653 1.5× 446 1.5× 161 1.3× 133 1.7× 80 1.6× 24 713
Rosmeri Kuhmmer Lazzaretti Brazil 13 104 0.2× 95 0.3× 114 0.9× 55 0.7× 18 0.4× 18 298
José Ramón Santos Spain 17 612 1.5× 487 1.7× 192 1.6× 177 2.3× 50 1.0× 40 796
Denise Sutherland‐Phillips United States 7 493 1.2× 374 1.3× 195 1.6× 100 1.3× 21 0.4× 13 827
Amelia S. Petry United States 7 367 0.9× 209 0.7× 50 0.4× 119 1.5× 64 1.3× 9 423

Countries citing papers authored by Magda Opsomer

Since Specialization
Citations

This map shows the geographic impact of Magda Opsomer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Magda Opsomer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Magda Opsomer more than expected).

Fields of papers citing papers by Magda Opsomer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Magda Opsomer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Magda Opsomer. The network helps show where Magda Opsomer may publish in the future.

Co-authorship network of co-authors of Magda Opsomer

This figure shows the co-authorship network connecting the top 25 collaborators of Magda Opsomer. A scholar is included among the top collaborators of Magda Opsomer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Magda Opsomer. Magda Opsomer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
MacBrayne, Christine E., Richard M. Rutstein, Andrew Wiznia, et al.. (2021). Etravirine in treatment-experienced HIV-1-infected children 1 year to less than 6 years of age. AIDS. 35(9). 1413–1421. 2 indexed citations
3.
Eron, Joseph J., Chloe Orkin, Joel E. Gallant, et al.. (2018). A week-48 randomized phase-3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients. AIDS. 32(11). 1431–1442. 67 indexed citations
4.
Opsomer, Magda, Dessislava I. Dimitrova, Simon Vanveggel, et al.. (2018). Evaluation of Cardiovascular Disease Risk in HIV-1–Infected Patients Treated with Darunavir. Drugs in R&D. 18(3). 199–210. 9 indexed citations
5.
6.
Violari, Avy, Rosa Bologna, Nagalingeswaran Kumarasamy, et al.. (2015). Safety and Efficacy of Darunavir/Ritonavir in Treatment-experienced Pediatric Patients. The Pediatric Infectious Disease Journal. 34(5). e132–e137. 13 indexed citations
7.
Kakuda, Thomas N., Herta Crauwels, Magda Opsomer, et al.. (2015). Darunavir/cobicistat once daily for the treatment of HIV. Expert Review of Anti-infective Therapy. 13(6). 691–704. 11 indexed citations
8.
Flynn, Patricia M., Stéphane Blanche, Carlo Giaquinto, et al.. (2014). Efficacy and Safety of Darunavir/Ritonavir at 48 Weeks in Treatment-naïve, HIV-1–infected Adolescents. The Pediatric Infectious Disease Journal. 33(9). 940–945. 20 indexed citations
9.
10.
Arathoon, Eduardo, As’ad E. Bhorat, Herta Crauwels, et al.. (2014). Week 48 results of a Phase IV trial of etravirine with antiretrovirals other than darunavir/ritonavir in HIV‐1‐infected treatment‐experienced adults. Journal of the International AIDS Society. 17(4S3). 19783–19783. 2 indexed citations
11.
Kakuda, Thomas N., Magda Opsomer, Maarten Timmers, et al.. (2014). Pharmacokinetics of darunavir in fixed‐dose combination with cobicistat compared with coadministration of darunavir and ritonavir as single agents in healthy volunteers. The Journal of Clinical Pharmacology. 54(8). 949–957. 40 indexed citations
12.
Tashima, Karen T., Gordon Crofoot, Frank Tomaka, et al.. (2014). Cobicistat-boosted darunavir in HIV-1-infected adults: week 48 results of a Phase IIIb, open-label single-arm trial. AIDS Research and Therapy. 11(1). 39–39. 48 indexed citations
13.
Tudor‐Williams, Gareth, Pedro Cahn, Kulkanya Chokephaibulkit, et al.. (2014). Etravirine in treatment‐experienced, HIV‐1‐infected children and adolescents: 48‐week safety, efficacy and resistance analysis of the phase II PIANO study. HIV Medicine. 15(9). 513–524. 19 indexed citations
14.
Kakuda, Thomas N., et al.. (2013). Bioequivalence of a Darunavir/Cobicistat Fixed-Dose Combination Tablet versus Single Agents and Food Effect in Healthy Volunteers. Antiviral Therapy. 19(6). 597–606. 29 indexed citations
15.
16.
Pelemans, W., et al.. (1994). Efficacy and safety of rilmenidine in elderly patients—Comparison with hydrochlorothiazide. The American Journal of Cardiology. 74(13). A51–A57. 10 indexed citations
17.
Naeije, Robert, et al.. (1993). Systemic and renal haemodynamic effects of angiotensin converting enzyme inhibition by zabicipril in young and in old normal men. European Journal of Clinical Pharmacology. 44(1). 35–39. 4 indexed citations
18.
Opsomer, Magda, et al.. (1990). Predictive Value of Serum Alkaline Dnase Activity Variations in Treatment of Head and Neck Cancer. Acta Oncologica. 29(2). 163–166. 12 indexed citations
19.
Opsomer, Magda, et al.. (1988). Characteristic variations of serum alkaline DNase activity in relation to response to therapy and tumor prognosis in human lung cancer. European Journal of Cancer and Clinical Oncology. 24(8). 1337–1343. 15 indexed citations
20.
Troxel, T.R., Magda Opsomer, & D.J. Kesler. (1984). The effect of days postpartum, indomethacin and oxytocin on prostaglandin metabolite concentrations in postpartum suckled beef cows. Theriogenology. 22(2). 187–196. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Pavel Khaykin Breakdown of academic impact, for papers by Lorant Leopold Breakdown of academic impact, for papers by Romina Quercia Breakdown of academic impact, for papers by David Pizzuti Breakdown of academic impact, for papers by S Staszewski Breakdown of academic impact, for papers by Frank Tomaka Breakdown of academic impact, for papers by Rosmeri Kuhmmer Lazzaretti Breakdown of academic impact, for papers by José Ramón Santos Breakdown of academic impact, for papers by Denise Sutherland‐Phillips Breakdown of academic impact, for papers by Amelia S. Petry
Rankless by CCL
2026